Our pipeline
We are dedicated to revolutionizing mental health care through innovative therapies targeting the endocannabinoid system. Our clinical trial pipeline focuses on developing treatment for psychiatric conditions.
CBD-ESPRIT
Cannabidiol vs. Placebo as add-on for maintenance in schizophrenia
Enhancing recovery in early schizophrenia – a multi-center, two- arm, double-blind, randomized phase II trial investigating cannabidiol vs. placebo as an add-on to an individualized antipsychotic treatment.
CONDITION
Remitted Early Phase Schizophrenia
INTERVENTION
Cannabidiol - given orally
PHASES
Phase II